Skip to main content

Kleberg Foundation Archives

Pancreatic cancer development

Aug. 31, 2017—Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease.

Read more


HDAC3 role in B-cell development

Aug. 3, 2017—The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies.

Read more


PET imaging to predict tumor response

Jun. 14, 2017—A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

Read more


New grants bolster Trauma program’s research initiatives

Feb. 9, 2017—Vanderbilt University Medical Center’s Division of Trauma, Emergency General Surgery and Surgical Critical Care was recently awarded two new research grants.

Read more


Kleberg Foundation grant bolsters cancer drug discovery efforts

Aug. 3, 2016—The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”

Read more


New lead for ovarian cancer treatment

Dec. 10, 2015—Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer.

Read more


Growth factor blockade targets breast tumors

Aug. 14, 2014—Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.

Read more


PET probe detects dying tumor cells

May. 8, 2014—A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine.

Read more


Upcoming Events

MORE EVENTS »